Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. [electronic resource]
Producer: 20170728Description: 1194-1202 p. digitalISSN:- 1527-7755
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carboplatin -- administration & dosage
- Cell Cycle Checkpoints
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Dacarbazine -- administration & dosage
- Disease-Free Survival
- Drug-Related Side Effects and Adverse Reactions -- economics
- Health Care Costs -- statistics & numerical data
- Humans
- Ipilimumab
- Markov Chains
- Melanoma -- drug therapy
- Models, Economic
- Nivolumab
- Paclitaxel -- administration & dosage
- Proto-Oncogene Proteins B-raf -- genetics
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Survival Rate
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.